多関節若年性特発性関節炎治療薬の世界市場（～2026年）

• 英文タイトル：Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY13950
• 出版社/出版日：QYResearch / 2020年11月30日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、111ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は多関節若年性特発性関節炎治療薬のグローバル市場について調査・分析したレポートです。種類別（エタネルセプトバイオシミラー、トシリズマブバイオシミラー、サリルマブ、アダリムマブバイオシミラー、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別多関節若年性特発性関節炎治療薬の競争状況、市場シェア
・世界の多関節若年性特発性関節炎治療薬市場：種類別市場規模 2015年-2020年（エタネルセプトバイオシミラー、トシリズマブバイオシミラー、サリルマブ、アダリムマブバイオシミラー、その他）
・世界の多関節若年性特発性関節炎治療薬市場：種類別市場規模予測 2021年-2026年（エタネルセプトバイオシミラー、トシリズマブバイオシミラー、サリルマブ、アダリムマブバイオシミラー、その他）
・世界の多関節若年性特発性関節炎治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他）
・世界の多関節若年性特発性関節炎治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他）
・北米の多関節若年性特発性関節炎治療薬市場分析：米国、カナダ
・ヨーロッパの多関節若年性特発性関節炎治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの多関節若年性特発性関節炎治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の多関節若年性特発性関節炎治療薬市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの多関節若年性特発性関節炎治療薬市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Biocon Ltd、Coherus BioSciences Inc、Livzon Pharmaceutical Group Inc、Momenta Pharmaceuticals Inc、Mycenax Biotech Inc、Oncobiologics Inc、Oncodesign SA、Panacea Biotec Ltd、Regeneron Pharmaceuticals Inc、Sandoz International GmbH、UCB SA
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Polyarticular Juvenile Idiopathic Arthritis Drug Market
The global Polyarticular Juvenile Idiopathic Arthritis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Polyarticular Juvenile Idiopathic Arthritis Drug Scope and Market Size
Polyarticular Juvenile Idiopathic Arthritis Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Polyarticular Juvenile Idiopathic Arthritis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Polyarticular Juvenile Idiopathic Arthritis Drug market is segmented into
Etanercept Biosimilar
Tocilizumab Biosimilar
Sarilumab
Adalimumab Biosimilar
Others

Segment by Application, the Polyarticular Juvenile Idiopathic Arthritis Drug market is segmented into
Hospital
Clinic
Others

Regional and Country-level Analysis
The Polyarticular Juvenile Idiopathic Arthritis Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Polyarticular Juvenile Idiopathic Arthritis Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Polyarticular Juvenile Idiopathic Arthritis Drug Market Share Analysis
Polyarticular Juvenile Idiopathic Arthritis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Polyarticular Juvenile Idiopathic Arthritis Drug business, the date to enter into the Polyarticular Juvenile Idiopathic Arthritis Drug market, Polyarticular Juvenile Idiopathic Arthritis Drug product introduction, recent developments, etc.

The major vendors covered:
Biocon Ltd
Coherus BioSciences Inc
Livzon Pharmaceutical Group Inc
Momenta Pharmaceuticals Inc
Mycenax Biotech Inc
Oncobiologics Inc
Oncodesign SA
Panacea Biotec Ltd
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
UCB SA

レポート目次

1 Study Coverage
1.1 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
1.2 Market Segments
1.3 Key Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Growth Rate by Type
1.4.2 Etanercept Biosimilar
1.4.3 Tocilizumab Biosimilar
1.4.4 Sarilumab
1.4.5 Adalimumab Biosimilar
1.4.6 Others
1.5 Market by Application
1.5.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size, Estimates and Forecasts
2.1.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue 2015-2026
2.1.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales 2015-2026
2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Competitor Landscape by Players
3.1 Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Manufacturers
3.1.1 Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Manufacturers (2015-2020)
3.1.2 Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Manufacturers
3.2.1 Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Polyarticular Juvenile Idiopathic Arthritis Drug Revenue in 2019
3.2.5 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Polyarticular Juvenile Idiopathic Arthritis Drug Price by Manufacturers
3.4 Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturing Base Distribution, Product Types
3.4.1 Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Polyarticular Juvenile Idiopathic Arthritis Drug Product Type
3.4.3 Date of International Manufacturers Enter into Polyarticular Juvenile Idiopathic Arthritis Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Type (2015-2020)
4.1.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2015-2020)
4.1.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Type (2015-2020)
4.1.3 Polyarticular Juvenile Idiopathic Arthritis Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Polyarticular Juvenile Idiopathic Arthritis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Application (2015-2020)
5.1.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2015-2020)
5.1.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Application (2015-2020)
5.1.3 Polyarticular Juvenile Idiopathic Arthritis Drug Price by Application (2015-2020)
5.2 Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Polyarticular Juvenile Idiopathic Arthritis Drug by Country
6.1.1 North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country
6.1.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Type
6.3 North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Polyarticular Juvenile Idiopathic Arthritis Drug by Country
7.1.1 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country
7.1.2 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Type
7.3 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug by Region
8.1.1 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Region
8.1.2 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Type
8.3 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Polyarticular Juvenile Idiopathic Arthritis Drug by Country
9.1.1 Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country
9.1.2 Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Type
9.3 Central & South America Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug by Country
10.1.1 Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country
10.1.2 Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Type
10.3 Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Biocon Ltd
11.1.1 Biocon Ltd Corporation Information
11.1.2 Biocon Ltd Description and Business Overview
11.1.3 Biocon Ltd Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.1.5 Biocon Ltd Related Developments
11.2 Coherus BioSciences Inc
11.2.1 Coherus BioSciences Inc Corporation Information
11.2.2 Coherus BioSciences Inc Description and Business Overview
11.2.3 Coherus BioSciences Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.2.5 Coherus BioSciences Inc Related Developments
11.3 Livzon Pharmaceutical Group Inc
11.3.1 Livzon Pharmaceutical Group Inc Corporation Information
11.3.2 Livzon Pharmaceutical Group Inc Description and Business Overview
11.3.3 Livzon Pharmaceutical Group Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.3.5 Livzon Pharmaceutical Group Inc Related Developments
11.4 Momenta Pharmaceuticals Inc
11.4.1 Momenta Pharmaceuticals Inc Corporation Information
11.4.2 Momenta Pharmaceuticals Inc Description and Business Overview
11.4.3 Momenta Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.4.5 Momenta Pharmaceuticals Inc Related Developments
11.5 Mycenax Biotech Inc
11.5.1 Mycenax Biotech Inc Corporation Information
11.5.2 Mycenax Biotech Inc Description and Business Overview
11.5.3 Mycenax Biotech Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.5.5 Mycenax Biotech Inc Related Developments
11.6 Oncobiologics Inc
11.6.1 Oncobiologics Inc Corporation Information
11.6.2 Oncobiologics Inc Description and Business Overview
11.6.3 Oncobiologics Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.6.5 Oncobiologics Inc Related Developments
11.7 Oncodesign SA
11.7.1 Oncodesign SA Corporation Information
11.7.2 Oncodesign SA Description and Business Overview
11.7.3 Oncodesign SA Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.7.5 Oncodesign SA Related Developments
11.8 Panacea Biotec Ltd
11.8.1 Panacea Biotec Ltd Corporation Information
11.8.2 Panacea Biotec Ltd Description and Business Overview
11.8.3 Panacea Biotec Ltd Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.8.5 Panacea Biotec Ltd Related Developments
11.9 Regeneron Pharmaceuticals Inc
11.9.1 Regeneron Pharmaceuticals Inc Corporation Information
11.9.2 Regeneron Pharmaceuticals Inc Description and Business Overview
11.9.3 Regeneron Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.9.5 Regeneron Pharmaceuticals Inc Related Developments
11.10 Sandoz International GmbH
11.10.1 Sandoz International GmbH Corporation Information
11.10.2 Sandoz International GmbH Description and Business Overview
11.10.3 Sandoz International GmbH Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.10.5 Sandoz International GmbH Related Developments
11.1 Biocon Ltd
11.1.1 Biocon Ltd Corporation Information
11.1.2 Biocon Ltd Description and Business Overview
11.1.3 Biocon Ltd Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Products Offered
11.1.5 Biocon Ltd Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Polyarticular Juvenile Idiopathic Arthritis Drug Market Estimates and Projections by Region
12.1.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Regions 2021-2026
12.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast (2021-2026)
12.2.1 North America: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast (2021-2026)
12.2.2 North America: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast (2021-2026)
12.2.3 North America: Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast (2021-2026)
12.3.2 Europe: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Polyarticular Juvenile Idiopathic Arthritis Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Polyarticular Juvenile Idiopathic Arthritis Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Polyarticular Juvenile Idiopathic Arthritis Drug Market Segments
Table 2. Ranking of Global Top Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Etanercept Biosimilar
Table 5. Major Manufacturers of Tocilizumab Biosimilar
Table 6. Major Manufacturers of Sarilumab
Table 7. Major Manufacturers of Adalimumab Biosimilar
Table 8. Major Manufacturers of Others
Table 9. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Polyarticular Juvenile Idiopathic Arthritis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Polyarticular Juvenile Idiopathic Arthritis Drug as of 2019)
Table 18. Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Polyarticular Juvenile Idiopathic Arthritis Drug Price (2015-2020) (USD/Pcs)
Table 21. Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Polyarticular Juvenile Idiopathic Arthritis Drug Product Type
Table 23. Date of International Manufacturers Enter into Polyarticular Juvenile Idiopathic Arthritis Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Share by Type (2015-2020)
Table 27. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Share by Type (2015-2020)
Table 29. Polyarticular Juvenile Idiopathic Arthritis Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Share by Application (2015-2020)
Table 32. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2015-2020)
Table 34. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2015-2020)
Table 38. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2015-2020)
Table 72. Biocon Ltd Corporation Information
Table 73. Biocon Ltd Description and Major Businesses
Table 74. Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Biocon Ltd Product
Table 76. Biocon Ltd Recent Development
Table 77. Coherus BioSciences Inc Corporation Information
Table 78. Coherus BioSciences Inc Description and Major Businesses
Table 79. Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Coherus BioSciences Inc Product
Table 81. Coherus BioSciences Inc Recent Development
Table 82. Livzon Pharmaceutical Group Inc Corporation Information
Table 83. Livzon Pharmaceutical Group Inc Description and Major Businesses
Table 84. Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Livzon Pharmaceutical Group Inc Product
Table 86. Livzon Pharmaceutical Group Inc Recent Development
Table 87. Momenta Pharmaceuticals Inc Corporation Information
Table 88. Momenta Pharmaceuticals Inc Description and Major Businesses
Table 89. Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Momenta Pharmaceuticals Inc Product
Table 91. Momenta Pharmaceuticals Inc Recent Development
Table 92. Mycenax Biotech Inc Corporation Information
Table 93. Mycenax Biotech Inc Description and Major Businesses
Table 94. Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Mycenax Biotech Inc Product
Table 96. Mycenax Biotech Inc Recent Development
Table 97. Oncobiologics Inc Corporation Information
Table 98. Oncobiologics Inc Description and Major Businesses
Table 99. Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Oncobiologics Inc Product
Table 101. Oncobiologics Inc Recent Development
Table 102. Oncodesign SA Corporation Information
Table 103. Oncodesign SA Description and Major Businesses
Table 104. Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Oncodesign SA Product
Table 106. Oncodesign SA Recent Development
Table 107. Panacea Biotec Ltd Corporation Information
Table 108. Panacea Biotec Ltd Description and Major Businesses
Table 109. Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Panacea Biotec Ltd Product
Table 111. Panacea Biotec Ltd Recent Development
Table 112. Regeneron Pharmaceuticals Inc Corporation Information
Table 113. Regeneron Pharmaceuticals Inc Description and Major Businesses
Table 114. Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Regeneron Pharmaceuticals Inc Product
Table 116. Regeneron Pharmaceuticals Inc Recent Development
Table 117. Sandoz International GmbH Corporation Information
Table 118. Sandoz International GmbH Description and Major Businesses
Table 119. Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. Sandoz International GmbH Product
Table 121. Sandoz International GmbH Recent Development
Table 122. UCB SA Corporation Information
Table 123. UCB SA Description and Major Businesses
Table 124. UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. UCB SA Product
Table 126. UCB SA Recent Development
Table 127. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 128. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share Forecast by Regions (2021-2026)
Table 129. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 130. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 131. North America: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 132. North America: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Europe: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 134. Europe: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Asia Pacific: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 136. Asia Pacific: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 137. Latin America: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 138. Latin America: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Middle East and Africa: Polyarticular Juvenile Idiopathic Arthritis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 140. Middle East and Africa: Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 142. Key Challenges
Table 143. Market Risks
Table 144. Main Points Interviewed from Key Polyarticular Juvenile Idiopathic Arthritis Drug Players
Table 145. Polyarticular Juvenile Idiopathic Arthritis Drug Customers List
Table 146. Polyarticular Juvenile Idiopathic Arthritis Drug Distributors List
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Polyarticular Juvenile Idiopathic Arthritis Drug Product Picture
Figure 2. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Etanercept Biosimilar Product Picture
Figure 4. Tocilizumab Biosimilar Product Picture
Figure 5. Sarilumab Product Picture
Figure 6. Adalimumab Biosimilar Product Picture
Figure 7. Others Product Picture
Figure 8. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Polyarticular Juvenile Idiopathic Arthritis Drug Report Years Considered
Figure 13. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Region in 2019
Figure 18. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Region in 2019
Figure 20. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Polyarticular Juvenile Idiopathic Arthritis Drug Revenue in 2019
Figure 22. Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type in 2019
Figure 25. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Type in 2019
Figure 27. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Price Range (2015-2020)
Figure 28. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application in 2019
Figure 30. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Application in 2019
Figure 32. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country in 2019
Figure 35. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Type in 2019
Figure 41. North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Application in 2019
Figure 42. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country in 2019
Figure 45. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country in 2019
Figure 46. Germany Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Type in 2019
Figure 57. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Application in 2019
Figure 58. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Region in 2019
Figure 62. China Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Type in 2019
Figure 85. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Application in 2019
Figure 86. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country in 2019
Figure 89. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Type in 2019
Figure 97. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Application in 2019
Figure 110. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed

以下、関連資料のご紹介

全身性特発性若年性関節炎治療の世界市場（～2026年）

Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04784 2020年11月20日 92Pages
当調査資料は全身性特発性若年性関節炎治療のグローバル市場について調査・分析したレポートです。種類別（アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス...

特発性低身長治療薬の世界市場（～2026年）

Global Idiopathic Short Stature Drug Market Insights and Forecast to 2026
MRC2-11QY01538 2020年11月20日 111Pages
当調査資料は特発性低身長治療薬のグローバル市場について調査・分析したレポートです。種類別（BBT-031、MMP-0201、ソマトロピン、ソマトロピンS、その他）市場規模、用途別（研究センター、病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、...

関節炎薬の世界市場（～2026年）

Global Arthritis Drug Market Insights and Forecast to 2026
MRC2-11QY02683 2020年11月20日 112Pages
当調査資料は関節炎薬のグローバル市場について調査・分析したレポートです。種類別（合成DMARD、生物学的DMARD、NSAID、コルチコステロイド、鎮痛薬）市場規模、用途別（小売薬局、病院薬局、ドラッグストア、Eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

血清反応陽性用関節リウマチ治療薬の世界市場（～2026年）

Global Seropositive Rheumatoid Arthritis Drug Market Insights and Forecast to 2026
MRC2-11QY09391 2020年11月25日 152Pages
当調査資料は血清反応陽性用関節リウマチ治療薬のグローバル市場について調査・分析したレポートです。種類別（非ステロイド性抗炎症薬、疾患修飾性抗リウマチ治療薬、生物製剤）市場規模、用途別（医療、科学研究、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシ...

乾癬性関節炎治療薬の世界市場（～2026年）

Global Psoriatic Arthritis Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY04407 2020年11月20日 93Pages
当調査資料は乾癬性関節炎治療薬のグローバル市場について調査・分析したレポートです。種類別（非ステロイド性抗炎症薬、疾患修飾性抗リウマチ薬、生物学的薬剤、酵素阻害剤）市場規模、用途別（病院、診療所、研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、...

慢性特発性骨髄線維症の世界市場（～2026年）

Global Chronic Idiopathic Myelofibrosis Market Size, Status and Forecast 2020-2026
MRC2-11QY11363 2020年11月25日 96Pages
当調査資料は慢性特発性骨髄線維症のグローバル市場について調査・分析したレポートです。種類別（化学療法、生物学的療法、その他）市場規模、用途別（病院、クリニック、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、...

関節リウマチ治療の世界市場（～2026年）

Global Rheumatoid Arthritis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04516 2020年11月20日 99Pages
当調査資料は関節リウマチ治療のグローバル市場について調査・分析したレポートです。種類別（対症療法、中間コルチコステロイド療法、疾患修飾性抗リウマチ薬療法）市場規模、用途別（病院薬局、小売薬局、ドラッグストア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシ...

若年性黄斑変性症治療の世界市場（～2026年）

Global Juvenile Macular Degeneration Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12457 2020年11月25日 99Pages
当調査資料は若年性黄斑変性症治療のグローバル市場について調査・分析したレポートです。種類別（アバシンカプタドペゴルナトリウム、エコーチオフェートヨウ化物、エミクススタト塩酸塩、FAB-111、その他）市場規模、用途別（クリニック、病院、在宅医療）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイ...

若年性黄斑変性症（シュタルガルト病）治療の世界市場（～2026年）

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12456 2020年11月25日 94Pages
当調査資料は若年性黄斑変性症（シュタルガルト病）治療のグローバル市場について調査・分析したレポートです。種類別（幹細胞治療、遺伝子治療、その他）市場規模、用途別（病院、眼科クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本...

特発性肺線維症（IPF）の世界市場（～2026年）

Global Idiopathic Pulmonary Fibrosis Market Size, Status and Forecast 2020-2026
MRC2-11QY12298 2020年11月25日 95Pages
当調査資料は特発性肺線維症（IPF）のグローバル市場について調査・分析したレポートです。種類別（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤）市場規模、用途別（病院、クリニック、外来手術センター、学術・研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フ...

全身性特発性若年性関節炎治療の世界市場（～2026年） Market Analysis and Insights: Global Systemic Idiopathic Juvenile Arthritis Treatment Market The global Systemic Idiopathic Juvenile Arthritis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Systemic Idiopath…
若年性黄斑変性症治療の世界市場（～2026年） Market Analysis and Insights: Global Juvenile Macular Degeneration Treatment Market The global Juvenile Macular Degeneration Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Juvenile Macular Degeneration Treat…
若年性黄斑変性症（シュタルガルト病）治療の世界市場（～2026年） Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy. Asia Pacific is expected to be the fastes…
特発性低身長治療薬の世界市場（～2026年） Market Analysis and Insights: Global Idiopathic Short Stature Drug Market The global Idiopathic Short Stature Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Idiopathic Short Stature Drug Scope and Market Size Idi…
関節炎薬の世界市場（～2026年） Arthritis is condition that causes pain and inflammation in joints. Around 100 different types of arthritis related conditions present globally and it is one of the leading cause of disability worldwide. The most common types of arthritis includes: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoart…